ClinicalTrials.gg

Program

BI 771716

A development code.

In Boehringer Ingelheim's pipeline, Antibody fragment. Its studies are mostly in Geographic Atrophy, led by Boehringer Ingelheim.

Furthest: phase 2, since Dec 5, 20242 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim20 open or runningphase 2since Dec 5, 2024Aug 17, 2023none ahead
  • Named in Boehringer Ingelheim’s own pipeline as BI 771716, phase 2, as of Aug 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 17, 2023First study: phase 1 study in Geographic AtrophyFirst studyNCT06006585 · 20 enrolled · United States
  2. Dec 5, 2024Phase 2 study in Macular DegenerationNCT06722157 · 202 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Antibody fragment”the company's pipeline, read by Claude · source

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06722157Macular Degeneration · United States2CompletedOct 26, 2026202
NCT06006585Geographic Atrophy · United States1CompletedMay 24, 202420

How it is read

Names in the registry

  • “BI 771716”, 2 entries

Codes read as this program: BI771716.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.